How many employees does Protagonist Therapeutics, Inc. have?

Protagonist Therapeutics, Inc. reported 132 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is up 4.8% from a year earlier.

What is Protagonist Therapeutics, Inc.'s revenue per employee?

Protagonist Therapeutics, Inc. brought in $46.0M of revenue in fiscal Dec 2025, which is $349K per employee. That ranks 29 of 39 companies we track in Biotechnology, where the median is $602K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Protagonist Therapeutics, Inc. employees and revenue per employee

PTGX · Biotechnology · $9.01B market cap

Protagonist Therapeutics, Inc. had 132 employees at the end of fiscal Dec 2025, up 4.8% from a year earlier. Revenue for the year was $46.0M, down 89.4% from a year earlier, or $349K per employee. Revenue fell while headcount grew.

Employees

132

+4.8% YoY

Revenue

$46.0M

-89.4% YoY

Revenue / employee

$349K

Peer median $602K

Rank in industry

29 of 39

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2017

Hover a year for the numbers.

PTGX employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	132	$46.0M	$349K	+4.8%	-89.4%
Dec 2024	126	$434M	$3.45M	+12.5%	+624.1%
Dec 2023	112	$60.0M	$536K	+6.7%	+125.7%
Dec 2022	105	$26.6M	$253K	-11.0%	-2.8%
Dec 2021	118	$27.4M	$232K	+49.4%	-4.4%
Dec 2020	79	$28.6M	$362K	+8.2%	+12293.1%
Dec 2019	73	$231,000	$3K	+14.1%	-99.3%
Dec 2018	64	$30.9M	$483K	+16.4%	+54.1%
Dec 2017	55	$20.1M	$365K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Protagonist Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
AMLX Amylyx Pharmaceuticals, Inc.	123	$87.4M	$710K	Contracting
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
PTGX Protagonist Therapeutics, Inc.	132	$46.0M	$349K	Hiring into decline
NUVB Nuvation Bio Inc.	298	$62.9M	$211K	Efficient growth
KYMR Kymera Therapeutics, Inc.	238	$39.2M	$165K	Hiring into decline
IBRX ImmunityBio, Inc.	691	$113M	$164K	Efficient growth
CYTK Cytokinetics, Incorporated	673	$88.0M	$131K	Efficient growth
RLAY Relay Therapeutics, Inc.	192	$15.4M	$80K	Leaner
PGEN Precigen, Inc.	160	$9.7M	$61K	Efficient growth

Every Healthcare company

Questions about Protagonist Therapeutics, Inc.

How many employees does Protagonist Therapeutics, Inc. have?: Protagonist Therapeutics, Inc. reported 132 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 25, 2026. That is up 4.8% from a year earlier.
What is Protagonist Therapeutics, Inc.'s revenue per employee?: Protagonist Therapeutics, Inc. brought in $46.0M of revenue in fiscal Dec 2025, which is $349K per employee. That ranks 29 of 39 companies we track in Biotechnology, where the median is $602K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare PTGX with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Protagonist Therapeutics, Inc.'s annual reports (Form 10-K), latest filed February 25, 2026. This is data, not a recommendation to buy or sell PTGX.